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Transcriptional signal cointegrators associate with transcription factors or nuclear receptors and coregulate tissue-specific gene transcrip-
tion. We report on recessive loss-of-function mutations in two genes (TRIP4 and ASCC1) that encode subunits of the nuclear activating
signal cointegrator 1 (ASC-1) complex. We used autozygosity mapping and whole-exome sequencing to search for pathogenic mutations
in four families. Affected individuals presented with prenatal-onset spinal muscular atrophy (SMA), multiple congenital contractures (ar-
throgryposis multiplex congenita), respiratory distress, and congenital bone fractures. We identified homozygous and compound-hetero-
zygous nonsense and frameshift TRIP4 and ASCC1mutations that led to a truncation or the entire absence of the respective proteins and
cosegregated with the disease phenotype. Trip4 and Ascc1 have identical expression patterns in 17.5-day-old mouse embryos with high
expression levels in the spinal cord, brain, paraspinal ganglia, thyroid, and submandibular glands. Antisensemorpholino-mediated knock-
downof either trip4orascc1 in zebrafishdisrupted thehighlypatternedandcoordinatedprocessofa-motoneuronoutgrowthandformation
ofmyotomes andneuromuscular junctions and led to a swimmingdefect in the larvae. Immunoprecipitationof the ASC-1 complex consis-
tently copurified cysteine and glycine richprotein1 (CSRP1), a transcriptional cofactor, which is known tobe involved in spinal cord regen-
eration upon injury in adult zebrafish. ASCC1mutant fibroblasts downregulated genes associated with neurogenesis, neuronal migration,
and pathfinding (SERPINF1, DAB1, SEMA3D, SEMA3A), as well as with bone development (TNFRSF11B, RASSF2, STC1). Our findings indi-
cate that the dysfunction of a transcriptional coactivator complex can result in a clinical syndrome affecting the neuromuscular system.Introduction
Arthrogryposis multiplex congenita (AMC) comprises a
heterogeneous group of disorders that has a prevalence
of 8.5/100,000 individuals and an incidence of 1/3,000–
5,000 births and shares multiple congenital joint contrac-
tures as a defining feature.1,2 AMC is caused by limited fetal
movement (akinesia) resulting from conditions that
impede intrauterine neuromuscular development.3 Much
has been learned from AMC-causing gene defects about
the development of the human neuromuscular system.
Mutations can affect the genes of structural proteins of
the contractile apparatus,4 trophic factors, proteins impli-
cated in pathfinding5,6 and myelination,7 receptor pro-
teins,8,9 or proteins involved in transmitter release.10
In six out of seven individuals from our study, AMC
occurred together with congenital bone fractures. From
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The Ameextremely rare conditionandaremainlydue to traumaoros-
teogenesis imperfecta.11 A retrospective birth register study
of 343,941 newborns from Sweden uncovered 68 cases of
multiple congenital contractures (incidence ~1/5,100).
Of these 68 children, 14 had amyoplasia (incidence
~1/45,000), 18 had different neuromuscular disorders (inci-
dence ~1/19,100), and only 2 had perinatal fractures (inci-
dence ~1/172,000), although it was not mentioned to
what group the latter two individuals belonged. Hall et al.
analyzed the clinical symptoms of amyoplasia, the most
frequent subform of AMC, and found a much higher fre-
quency of congenital bone fractures among these children,
in the range of ten percent.12 Other rare disorders in which
AMC associates with congenital bone fractures occur with
mutations in UBA1 (formerly UBE1, X-linked spinal
muscular atrophy type 2 [SMAX2] [MIM: 301830]),13,14
FKBP10 (Bruck syndrome type 1 [MIM: 259450]),15 and
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[LCCS2] [MIM: 607598])16 and in several forms of nemaline
myopathy.17–19 Although the most severe form of infantile
spinal muscular atrophy (SMA type 1, Werdnig Hoffmann
disease [MIM: 253300]) is often associated with fetal akine-
sia, congenital bone fractures seem to be a rarity in this con-
dition. In these children, fractures might occur later in life
due to inactivity. We only found a single publication in
which a case of SMA type 1 plus congenital bone fractures
had been verified on the molecular level through detection
of an SMN1 deletion.20 In most published cases of SMA
plus congenital bone fractures, SMN1 deletions had been
excluded.21–24 Hence, we set out to search for mutations in
other genes that might involve neuromuscular develop-
ment as well as bone metabolism in three families with six
affected children who had AMC plus congenital fractures.
Gene mapping and whole-exome sequencing (WES) re-
vealed mutations in two genes that encode subunits of a
transcriptional signal cointegrator complex.
Transcriptional signal cointegrators associate with tran-
scription factors or with nuclear receptors in multi-pro-
tein complexes and are able to bi-directionally affect the
link between receptor and transcription machinery, either
as corepressors or coactivators. They enable the functional
integration of multiple transcription factors25 and thus
fine-tune cell metabolism and transcription depending
on environmental cues26 or provide tissue specificity.27
Over the past few years, a number of studies have shown
that coactivator complexes are often bi-functional pro-
teins that do not only coactivate transcription mediated
by specific transcription factors, like nuclear hormone re-
ceptors, but also participate in pre-mRNA processing and
regulation of splicing.28 The tetrameric ASC-1 transcrip-
tional cointegrator complex is composed of the following
four subunits.29 TRIP4 (thyroid receptor interacting
protein 4 [MIM: 604501]) contains a conserved cysteine-
rich Zn-chelating domain, which binds transcription
factors,29 and a conserved C-terminal domain, which har-
bors a RNA-binding PUA domain30 thought to be an
ancient structural motif for RNA-protein interactions.
ASCC1 (ASC-1 complex, subunit 1 [MIM: 614215])
has an RNA-binding KH domain fused to a 2H RNA-phos-
phoesterase.29,31 Not much is known about the ~100 kDa
subunit ASCC2 (ASC-1 complex subunit 2 [MIM:
614216]). The largest subunit of ~200 kDa, ASCC3
(ASC-1 complex subunit 3 [MIM: 614217]), is an RNA
helicase and shows paralogy to the small nuclear ribonu-
cleoprotein 200, which is involved in RNA splicing.
Hence, the ASC-1 complex is likely to be a ribonucleopro-
tein complex that participates in transcriptional coactiva-
tion, as well as in RNA processing events.Methods
Ethics
Human samples were collected according to guidelines laid down
in the Declaration of Helsinki in the amended version of 2013. All474 The American Journal of Human Genetics 98, 473–489, March 3caretakers provided written informed consent for all investiga-
tions of the study (IRB approval of the Charite´ EA2/092/06). Zebra-
fish were raised and used in compliance with the guidelines
approved by the animal care and use committee at the National
Institute of Genetics (Japan).Haplotype and Mutation Analysis
Autozygosity mapping32 was performed with members of families
A, B, and D (Figures S3–S5, members indicated by an asterisk on
the pedigrees in Figure 2). WES was done in three index case indi-
viduals (B.II_01, D.II_02, D.II_03), as previously described.33 DNA
analyses were done with genomic DNA from blood leukocytes. For
SNP analysis, we used the GeneChip Human Mapping 250K SNP
Array (Affymetrix) and analyzed each separate family with the
HomozygosityMapper software for autozygous regions that were
only present in affected children and not in unaffected family
members.32
ForWES, we captured the exonic sequences by using the SeqCap
EZ Human Exome Library v.3.0 (NimbleGen) and sequenced them
on a HiSeq2000 (Illumina) machine. The paired-end reads were
aligned to the 1000 Genomes GRCh37.p11 human reference
sequence with the Burrows-Wheeler Aligner (BWA)-MEM
v.0.7.134 and then fine-adjusted and called for deviations from
the human reference with the Genome Analysis Toolkit (GATK)
v.2.7 in all exonic5 50 bp flanking regions.35 For coverage details,
see Table S2. The resulting variants were filtered for homozygosity
(e.g., the absence of more than four homozygotes in the 1000
Genomes Project or of more than 20 homozygotes in the Exome
Aggregation Consortium [ExAC] database) and the presence of
the variant in the autozygous interval. These variants were then
assessed by the MutationTaster software for potential pathoge-
nicity.36 Variants and their segregation were verified by bi-direc-
tional Sanger sequencing with the BigDye Terminator method
(Applied Biosystems). Subsequently, we searched for TRIP4 and
ASCC1mutations in 11 unrelated children with AMC, respiratory
distress, and congenital bone fractures by performing sequence
analysis of the entire open reading frame and intron-exon borders
of both genes; genomic primers are listed in Table S8.Analysis of TRIP4 Splice Isoforms
In order to explain the identity of the additional bands on the
TRIP4 western blot, we used RT-PCR. mRNA from muscle tissue
of affected children and control indiviuduals was reversely tran-
scribed into cDNA and amplified with various primer combina-
tions with forward primers (located at exons 1–5) and reverse
primers (located at exons 8–13). Resulting PCR products were
subcloned and subjected to bi-directional automatic Sanger
sequencing. Resulting sequence fragments were aligned to the
TRIP4 reference sequence with the STAR v.2.4.0 software, which
is able to identify novel splice junction sites.5 For the identifica-
tion of different splicing patterns in RNA-seq datasets from the
GEO repository (Figure 3), we used the STAR v.2.4.0 aligner fol-
lowed by analysis with the Cufflinks v.2.2.1 software suite.37Histology
Cryosections from muscle biopsy specimens were stained with
Go¨mo¨ri trichrome, H&E non-specific esterase, and ATPases pre-
incubated at pH 4.3, 4.6, and 9.4, as well as with primary anti-
bodies directed against myosin heavy chain: MHCslow, MHCfast,
MHCneo, and MHCdev. Signals were visualized with appropriate
secondary antibodies and the diaminobenzidine system. Zebrafish, 2016
morphants were anesthetized at 48 hours post fertilization (hpf) in
0.02% tricaine (Sigma), fixed in cacodylate-buffered (pH 7.2) 2%
glutaraldehyde, and prepared for electron microscopy as previ-
ously described.38 The skeletal muscle was likewise processed for
electron microscopy. For antibodies, see Table S9.
Western Blot
Western blot was performed with protein extracts from muscle
and fibroblasts as previously described.39 We used antibodies
against TRIP4 and ASCC1. Anti-pan-Actin was used as loading
control for muscle and b-tubulin for fibroblasts. Bands were visu-
alized by chemiluminescence with peroxidase-labeled secondary
antibodies. For antibodies, see Table S9.
Cell Sub-fractionation
Fibroblasts were yielded from nearly confluent plastic culture
flasks by trypsination. Cross linking was done in DMEM with
1% formaldehyde for 10 min on ice. The reaction was stopped
by adding glycine to a concentration of 130 mM, and the cells
were spun down at 250 3 g for 7 min. The pellet was resuspended
in LF buffer (50 mMTris-HCl [pH 7.5], 150mMNaCl, 5 mMEDTA,
0.5% NP40, 1.15% Triton X-100, one Complete tablet [Roche])
and incubated for 10 min on ice. The cell suspension was then
transferred into a Dounce tissue grinder where cells were broken
by 10 up and down strokes and centrifuged for 10 min at 4C at
3,0003 g. The supernatant was kept at80C as the cytosolic frac-
tion. The pellet containing the nuclei was resuspended in freshly
prepared nuclear lysis buffer (10 mM Tris-HCl [pH 8.0], 100 mM
NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate, 0.5%
N-lauroylsarcosine, one Complete tablet) and sonicated 10 times
for 10 s on ice. Finally, a 1/10 volume of Triton X-100 was added
and a centrifugation at 16,000 3 g for 1 min was performed to re-
move debris. The supernatant was kept as the nuclear fraction.
Immunoprecipitation
500 mg protein of the nuclear fraction were mixed with 2 mg of spe-
cific antibody and incubated in 500 ml nuclear lysis buffer on a ro-
tator at 4C overnight. Washed 50 ml Protein-G Sepharose beads
were then added and incubated on a rotator at 4C overnight to
let the beads bind to the specific antibodies. Beads were then
spun down at 2,000 3 g at 4C for 2 min. The supernatant con-
tained the unbound fraction. The bead pellet was then washed
six times with wash buffer (50 mM HEPES-KOH [pH 7.55], 1 mM
EDTA, 1.0% NP40, 0.7% Na-deoxycholate, 500 mM LiCl). For
western blot, the beads were finally washed once with TE buffer
(10 mM Tris-HCl [pH 8.0], 1 mM EDTA, 50 mM NaCl). Protein
was eluted from the beads with elution buffer (50 mM Tris-HCl
[pH 8.0], 10 mM EDTA, 1.0% SDS). Remaining beads were spun
down at 2,000 3 g at 4C for 2 min, and the supernatant was
used for SDS-PAGE. For mass spectrometry, the beads were finally
washed once with 50 mM ammonium-bicarbonate (pH 8.0) and
spun down at 2,000 3 g for 2 min at 4C. After removal of the su-
pernatant, the pellets were frozen on dry ice.
Trip4 and Ascc1 In Situ Expression Analysis in Mice
and Zebrafish
Studies of Trip4 and Ascc1 gene expression were done in axial and
sagittal sections of whole C57BL6/J mouse embryos (embryonic
day 17.5 [E17.5]) by in situ hybridization as previously des-
cribed.40 Mouse embryos were embedded in TissueTek (Sakura),
and longitudinal and axial sections were prepared on a cryostat.The AmeRiboprobes of ~600 bp length were generated by RT-PCR from
mouse muscle with tailed primers (Table S8) and cloned into the
pCR-Script vector (Clontech). After linearization of the vector,
antisense and sense DIG-labeled probes were generated with T3
and T7 RNA polymerase (DIG RNA Labeling Kit, Roche), respec-
tively. Hybridization was performed overnight at 60C followed
by a colorimetric reaction at room temperature (24–48 hr). Slides
were photographed with a 203 lens on a DMI4000 (Leica) micro-
scope. Single visual fields were joined by the tiling-software
(Image-Pro Premier v.9.1) of the microscope to generate the
cross-sectional image of the spinal cord and adjacent structures
(Figure 4, Figures S6 and S7). Whole-mount in situ hybridization
of zebrafish was performed as previously published,6 with trip4
and ascc1 DIG-labeled antisense probes, and labeling with the
respective sense probes did not detect any significant signal.Functional Analysis in Zebrafish
MO-Mediated Knockdown of trip4 and ascc1
Two different antisense morpholino oligonucleotides (MOs) were
designed against the splice acceptor sites of zebrafish trip4 (bound-
ary of intron 4 and exon 5) and ascc1 (boundary of intron 3 and
exon 4) (Figures S8–S10). These antisense MOs and a standard
negative control MO were purchased from Gene Tools. The se-
quences of these MOs and the control MO are depicted on Table
S8. Zebrafish embryos were injected with 5 ng of MOs at the
one- or two-cell stage in three independent trials and studied as
previously published.6 At these dosages, the control MO produced
no discernible phenotype change.
Quantification of MO-Mediated trip4 and assc1 Knockdown on the
mRNA Level
Total RNA was extracted from a mixture of five MO-injected em-
bryos and subjected to RT-PCR with the SuperScript III kit (Life
Technologies) for reverse transcription. The number of reaction
cycles for PCR was 23 for trip4 and ascc1 and 18 for bactin. All
primer sequences are provided in Table S8. Quantitative analysis
was done by measurement of band intensities of trip4, ascc1, and
bactin with the ImageJ software, and p values were calculated
with the t test.
Quantification of MO-Mediated trip4 and assc1 Knockdown on the
Protein and Morphological Levels
For morphological analysis of a-motoneurons and neuromuscular
junctions, zebrafish embryos (36 hpf) were anaesthetized in 0.02%
tricaine (Sigma) and fixed in 4% paraformaldehyde (Sigma) at 4C
overnight and subjected to immunostaining as described previ-
ously (Figure 5).6 The following antibodies and labeling reagents
were used: anti-synaptotagmin (znp-1, 1:100), AlexaFluor488-con-
jugated anti-mouse immunoglobulin G (IgG, 1:1,000), and
AlexaFluor594-conjugated a-bungarotoxin (1:1,000). Fluorescent
images were captured with a confocal microscope (SP5, Leica).
For antibodies, see Table S9. To quantify the reduction of neuro-
muscular junctions in the morphants, we densitometrically
measured the intensities of the a-bungarotoxin staining in control
and morphant zebrafish larvae by using ImageJ. Statistic analysis
was done by t test.
Movement Analysis of Zebrafish
At 1 dpf, the chorion of the embryos was removed to allow touch
access to the embryos. Embryos showing retarded development or
developmental malformations, which were even seen in un-in-
jected wild-type clutch, were removed before assay. Tactile stimu-
lationwas applied to the tail with a forceps (Movies S1, S2, and S3).
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recorded at 30 hpf with a high-speed camera at 200 frames per sec-
ond (HAS-220, Ditect).41 The normal touch response of control
morphants at 1 dpf is a vigorous coiling behavior, twisting their
tail to the trunk (‘‘full coil’’), but ascc1 and trip4 morphants dis-
played only a faint twitch without coiling their tail to the trunk
(‘‘partial coil’’). The ratio of abnormal embryos showing partial
coil to total embryos in the three experimental trials is provided
in Table S3. Statistic analysis was done by the c2 test.
Rescue of MO-Knockdown with trip4 and ascc1 Constructs
Full-length zebrafish trip4 and ascc1 cDNAs were cloned into the
pCS2þ zebrafish expression vector with the oligonucleotide
primers detailed in Table S8. The trip4 nonsense mutation leading
to a truncation of the protein (zebrafish, p.Lys265*; corresponding
alteration in humans, p.Arg278*) and the ascc1 frameshift muta-
tion, also leading to a truncation of the protein (zebrafish,
p.Glu53Glyfs*) were introduced by site-directed mutagenesis.
100 pg of trip4 or ascc1 wild-type and mutant RNA were then in-
jected into zebrafish embryos along with trip4 or ascc1 MOs, and
the morphants were assayed for touch response and motoneuron
and neuromuscular junction labeling (Figure S11, Table S5).Cell Culture
Low passage skin fibroblasts of two affected children and four age-
matched control individuals were grown to semi-confluency in
DMEM supplemented with 15% fetal bovine serum (FBS) at
37C in a 5% CO2 atmosphere. After being washed with PBS, the
cells were incubated with DMEM supplemented with 0.5% FBS
over 24 hr for serum starvation. A fibroblast pellet was yielded after
this period (time point ¼ 00W). After being washed with PBS, the
other culture dishes were incubated with DMEM supplemented
with 15% FBS, and aliquots of cells were yielded exactly 30 min
(time point ¼ 30W) and 60 min (time point ¼ 60W) later. All pel-
lets were flash frozen in liquid nitrogen and stored at 80C until
further use.Global mRNA Expression Profiling
Skin fibroblasts of affected children (D:II_2 and D:II_3) and of age-
matched control indiviuduals (n ¼ 4) were processed as described
above. Total RNA was prepared from the frozen pellets with the
standard TRIzol (Life Technologies) protocol. Quality of the RNA
was controlled via the 2100 Bioanalyzer (Agilent). RNA was
hybridized, according the manufacturer’s instructions, on the
GeneChip Human Gene 2.0 ST Array (Affymetrix), which repre-
sents 40,716 human RefSeq transcripts, including 30,654 tran-
scripts which are annotated as protein coding. The chips were
scanned with the 428 Scanner (Affymetrix) and data were pro-
cessed with the Affymetrix GeneChip Command Console Soft-
ware (AGCC) to produce the CEL files that could be uploaded to
the GenePattern platform for further downstream analysis and
visualization.42 We first inspected those genes that are known
downstream targets of serum response factor (SRF), which, how-
ever, failed to show any difference in serum-dependent regulation
between affected children and control individuals (Figure S12).
Next, we identified those genes that were significantly up- and
downregulated in the samples from affected children in compari-
son to those from control individuals. In order to control for mul-
tiple testing, we only considered genes as significantly regulated if
they had a false discovery rate (FDR) below 0.01. The raw data of
this experiment can be accessed from the GEO database (GEO:
GSE67627). Pathway and gene network analysis of the regulated
genes was performed with AmiGO2.43476 The American Journal of Human Genetics 98, 473–489, March 3Statistics
Forcomparisonofnormallydistributedvalues,weusedthe t test, and
for not normally distributed values, either the c2 or the nonpara-
metric Mann-Whitney U test. To control for multiple testing in the
gene expression studies, we calculated the FDR,44 and differences
in gene expressionwere considered significant if the FDRwas<0.01.Results
Clinical Presentation in Eight Individuals from Four
Families
We describe here a cohort of seven individuals who were
born with distal and proximal joint contractures, as well
as generalized muscle atrophy and fractures of their long
bones (humerus and femur), and one aborted fetus. Deep
tendon reflexes were absent, muscles did not contract
upon electrical nerve stimulation, and neurography re-
vealed axonal neuropathy in these indiviudals. Respiratory
distress, diaphragmatic eventration and pulmonary hypo-
plasia necessitatedmechanical ventilation soon after birth.
Dysphagia required gavage feeding. For a detailed compar-
ison of clinical symptoms, see Table 1. Most children died
from respiratory failure between 2 weeks and 16 months of
life. One child died from acute heart failure. Additional
variable features included premature birth, microretrogna-
thia, hypertelorism, a high-arched palate, secundum atrial
septal defect, patent ductus arteriosus, and cardiomyopa-
thy. In the affected children from family D, cerebral MRI
had been performed and revealed a simplified gyral pattern
of the cerebral cortex (Figure 1).
Muscle biopsy samples from four children were available
for re-analysis (Figure 1): the muscle fibers were reduced in
size, showed increased fiber-size variation, and were much
more immature than samples from age-matched control in-
dividuals. The affected childrens’ type I fibers were clustered
ingroups, in comparison to the checkerboardpattern incon-
trol individuals, which is a characteristic finding in prenatal
SMA (Figure 1). In one individual, postmortem histology of
the spinal cord was available and revealed numerous
apoptotic a-motoneurons in the anterior horns at different
levels (Figure 1). Sural nerve biopsy from two children
showednormaldensityofmyelinatedfiberswithin the range
of published reference values46–48 (Figures S1 and S2, Table
S1), but also showed signs of unmyelinated axon loss
(Figure 1). The average axon diameters were increased
in one individual from family B, but in the range of a
normal age-matched control in an individual from
family D (Figure S2). On X-ray, the bones of individual
D.II_3 had failed to develop callus after 14 days of splinting.
Subperiostal new bone formation would be expected after
11 days at the latest, and even earlier in young infants.49
Bone mineralization and alkaline phosphatase activities
were normal.
Autozygosity Mapping and WES
Even though families A and B denied consanguinity, we
assumed a founder haplotype due to their common, 2016
Table 1. Clinical Data of the Investigated Families
Family A Family B Family C Family D Total
Country of origin Kosovo Kosovo Albania Turkey –
Gene involved TRIP4 TRIP4 TRIP4 ASCC1 –
Mutation on the cDNA level c.760C>T c.832C>T c.760C>T c.832C>T c.157dupG –
Predicted protein alteration p.Arg254* p.Arg278* p.Arg254* p.Arg278* p.Glu53Glyfs19* –
Number of affected individuals n ¼ 2 n ¼ 2 þ (1)a n ¼ 1 n ¼ 2 n ¼ 7 þ (1)a
Prenatal Manifestation: HPO ID
Decreased or absent fetal movement: 1558 n ¼ 2 n ¼ 2 ND n ¼ 2 n ¼ 6/6, 100%
Polyhydramnios: 1561 n ¼ 0 n ¼ 0 ND n ¼ 2 n ¼ 2/6, 33%
Oligohydramnios: 1562 n ¼ 2 n ¼ 1 ND n ¼ 0 n ¼ 3/6, 50%
Premature birth (< 37 weeks): 1622 n ¼ 1 n ¼ 1 ND n ¼ 2 n ¼ 4/6, 67%
Nervous System: HPO ID
Severe muscular hypotonia: 6829 n ¼ 2 n ¼ 2 n ¼ 1 n ¼ 2 n ¼ 7/7, 100%
Areflexia: 1284 n ¼ 2 ND ND n ¼ 2 n ¼ 4/4, 100%
Muscle weakness: 1324 n ¼ 2 n ¼ 2 ND n ¼ 2 n ¼ 6/6, 100%
Global developmental delay: 1263 n ¼ 2 n ¼ 2 ND n ¼ 2 n ¼ 6/6, 100%
Dysphagia: 2015 n ¼ 2 n ¼ 2 ND n ¼ 2 n ¼ 6/6, 100%
Abnormal cortical gyration: 2536 ND ND ND n ¼ 2 n ¼ 2/2, 100%
Head and Neck: HPO ID
Microretrognathia: 0308 n ¼ 2 n ¼ 2 ND n ¼ 0 n ¼ 4/6, 67%
Hypertelorism: 0316 n ¼ 2 n ¼ 1 ND n ¼ 0 n ¼ 3/6, 50%
High palate: 0218 n ¼ 2 n ¼ 1 ND n ¼ 0 n ¼ 3/6, 50%
Narrow mouth: 0160 n ¼ 2 n ¼ 0 ND n ¼ 0 n ¼ 2/6, 33%
Cardiovascular System: HPO ID
Patent foramen ovale: 1655 n ¼ 0 n ¼ 1 ND n ¼ 2 n ¼ 3/6, 50%
Secundum atrial septal defect: 1684 n ¼ 2 n ¼ 0 ND n ¼ 0 n ¼ 2/6, 33%
Patent ductus arteriosus: 1643 n ¼ 2 n ¼ 1 ND n ¼ 2 n ¼ 5/6, 83%
Cardiac failure: 1635 n ¼ 1 n ¼ 0 ND n ¼ 0 n ¼ 1/6, 17%
Cardiomyopathy: 1638 n ¼ 1 n ¼ 1 ND n ¼ 0 n ¼ 2/6, 34%
Respiratory System: HPO ID
Neonatal respiratory distress: 2643 n ¼ 2 n ¼ 2 n ¼ 1 n ¼ 2 n ¼ 7/7, 100%
Pulmonary hypoplasia: 2089 n ¼ 0 n ¼ 2 ND n ¼ 2 n ¼ 4/6, 67%
Musculo-skeletal System: HPO ID
Multiple prenatal fractures: 5855 n ¼ 2 n ¼ 1 ND n ¼ 2 n ¼ 5/6, 83%
Arthrogryposis multiplex congenita: 2804 n ¼ 2 n ¼ 3 n ¼ 1 n ¼ 2 n ¼ 8/8, 100%
Muscle fiber immaturity: NA n ¼ 1 n ¼ 2 ND n ¼ 1 n ¼ 4/4, 100%
Muscle fiber size variation and atrophic fibers: 3557 n ¼ 1 n ¼ 2 ND n ¼ 1 n ¼ 4/4, 100%
The families correspond to those in Figure 2. Abbreviations are as follows: HPO ID, Human Phenotype Ontology identifier; NA, not available; ND, not
determined.45
aFor Family B, the number in parentheses refers to an aborted fetus.Kosovan origin and performed autozygosity mapping.
Their shared autozygous region comprised 38 protein-cod-
ing genes (Figures S3–S5). Via WES of individual B.II_01,The Amewe found a homozygous nonsense mutation, c.832C>T
(p.Arg278*), in TRIP4 (chr15:64,701,816C>T [GRCh37],
exon 7 [GenBank: NM_016213.4]). Genotype-phenotyperican Journal of Human Genetics 98, 473–489, March 3, 2016 477
Figure 1. Clinical Presentation of the
Affected Children
(A and B) Axial T2-weighted cranialMRI images
of affected children D.II_02 (A) (at a corrected
gestational age of 39 weeks) and D.II_03 (B)
(at a corrected gestational age of 37 weeks)
with a simplified gyral pattern of the frontal
lobes and enlargement of the external CSF
spaces. Myelination of the brain stem and the
basal ganglia is normal.
(C) X-ray of the bilateral congenital femoral
fractures of individual D.II_03.
(D) Muscle histology demonstrates a reduction
in fiber size and an increase in fiber-size varia-
tion in two individuals with a TRIP4 and
ASCC1 mutation, in contrast to fiber size and
variation in an age-matched control individ-
ual. The grouping of the larger type I fibers
(marked by MHCslow), in contrast to a normal
checkerboard pattern in the control in-
dividual, is characteristic for prenatal SMA.
The intense staining of the muscles of the
affected children for MHCdev highlights their
immaturity.
(E) Ultrastructure of a sural nerve biopsy spec-
imen with normal myelinization but with
loss of unmyelinated axons as documented
by ‘‘empty’’ pouches (open triangles).
(F) Presence of multiple intensely stained
apoptotic a-motoneurons in the anterior
horn of the spinal cord in a postmortem
sample.segregation was verified by Sanger sequencing of the entire
family, including DNA from a fetus, who had been aborted
at 27 weeks and 3 days, after joint contractures were478 The American Journal of Human Genetics 98, 473–489, March 3, 2016observed on ultrasound imaging
(Figure 2). Sequencing of TRIP4 in family
A also revealed a nonsense mutation
(c.760C>T [p.Arg254*]), albeit unexpect-
edly, at a different position (chr15:
64,698,591C>T [GRCh37], exon 6), and
homozygosity of this mutation segre-
gated with the disease. Both mutations
were absent in the 1000 Genomes Project
as well as in 135 ancestry-matched in-
house exomes. The p.Arg278* truncation
was present in heterozygous form in
2/121,356 alleles of the ExAC database
(accessed November 2015), in two indi-
viduals of European and African descent,
whereas the p.Arg254* truncation was
not listed.
Despite a similar clinical phenotype,
autozygosity mapping located the disease
locus of family D not on chr15, but on
chr10. UsingWES, we discovered a frame-
shift mutation, c.157dup (p.Glu53Glyfs*
19), in ASCC1 (chr10:73,970,544_
5insC [GRCh37], exon 3 of ASCC1-003
[Ensembl: ENST00000317168] [GenBank:NM_001198800.2]) that was homozygous only in the
affected children (Figure 2). This mutation is present in het-
erozygous form in2/120,662 alleles of the ExACdatabase, in
Figure 2. Pedigrees of the Families and Molecular Genetic Findings
(A) The pedigrees of all investigated families with their respective genotypes are depicted below the symbols. Individuals marked with an
asterisk were used for autozygosity mapping.
(B) Variants identified by WES were verified by Sanger sequencing for segregation in all family members. Below the electropherograms,
the reading frame of the respective amino acids is provided in the three letter code. Both TRIP4mutations resulted in a premature termi-
nation codon, whereas the ASCC1mutation led to a frameshift with a termination codon after insertion of 19 non-original amino acids.
(C) Western blot of a muscle protein extract from two individuals with a TRIP4mutation and from a control individual. The premature
termination codons in both affected children lead to upregulation of an alternative splice isoform at ~53 kDa that excludes both mutant
positions. Anti-pan-Actin band density was used as a loading control.
(D) Western blot of a protein extract from cultured fibroblasts of both children from family D and of two control individuals. The
blot demonstrates the complete absence of the ASCC1 band in the affected children. b-tubulin band density was used as a loading
control.
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Figure 3. Splice Isoforms of TRIP4 and
ASCC1
(A) Genomic structure of TRIP4 (not drawn
to scale). The introns are indicated by gray
lines.
(B) The exons included into the various
mRNA splice isoforms are depicted in
green, and the red box indicates a frame-
shift.
(C) Sequence traces of the exon splice
junctions. Their respective localization is
marked on (B). The alternative splice
acceptor site in exon 7 is highlighted by
a red box.
(D) Genomic structure of ASCC1 (not
drawn to scale).
(E) The transcript encoding the 41 kDa
ASCC1 is the most abundant. Exon 3b,
which contains a missense mutation in
5.4% of the ExAC alleles and leads to the
truncation of the protein (p.Ser78*), is
only present in a rare ASCC1 45 kDa splice
variant found in 0%–2% of the indicated
GEO RNA-seq datasets.two individuals of European and Latino descent. Interest-
ingly, the ExAC database lists a variant in ASCC1
(rs11000217) in 896/16,490 alleles (59 of them homozy-
gotes), mainly in individuals from African or South Asian
descent, that causes a truncation of ASCC1 (p.Ser78*).
Such a findingmight put into question the essential impor-
tance of ASCC1 for the ASC-1 complex. However, a tran-
scriptomic analysis of RNA-seq datasets from muscle and
brain revealed that this variant (dbSNP: rs11000217) resides
in an exon that is only included in 0%–2%of the transcripts
from theASCC1 locus (exon 3b, Figure 3), whereas the exon
3a that carries the mutation of the affected children in our
study is present in >95% of the transcripts.
Cohort screening of TRIP4 and ASCC1 in 11 unrelated
affected children with the appropriate phenotype revealed
an additional individual (C:II_05), who also originated
from the Balkans (Albania) and carried both TRIP4 muta-
tions in compound heterozygous state (Figure 2).
In order to further exclude mutations in other (known)
genes that might have an influence on the phenotype of
our affected children, we specifically searched within the
autozygous regions of families A, B, and D for variants in
genes that were associated in the Human Phenotype
Ontology45 with ‘‘arthrogryposis, HP:0002804,’’ ‘‘fractures,
HP:0003084,’’ ‘‘spinal muscular atrophy, HP:0007269,’’480 The American Journal of Human Genetics 98, 473–489, March 3, 2016‘‘muscle weakness, HP:0001324,’’ or
with ‘‘abnormity of cortical gyration,
HP:0002536,’’ but did not find any
other potentially pathogenic vari-
ants, either in heterozygous or in
homozygous states.
Given that cryo-muscle samples
were available from individuals
A:II_02 and B:II_05, we studied the ef-
fect of the mutation on the proteinlevel bywestern blot.Whereas, in normalmuscle, we found
two bands at ~40 and ~70 kDa and an additional very weak
band at ~53 kDa, both individuals exhibited bands at
~53 kDa and ~36 kDa, with absence of the ~40 kDa and
~70 kDa bands (Figure 2). Interestingly, both mutant
TRIP4 bands migrated at the same molecular size despite
the fact that the premature termination codons were
located at different positions. RT-PCR analysis of different
TRIP4 splice isoforms (Figure 3) revealed the activation of
a cryptic splice acceptor site leading to a novel isoform
with skipping of exons 6 and part of exon 7 that preserved
the reading frame but excluded both missense mutations.
This splice isoform seems to be upregulated inmutant cells,
whereas the full-length transcript was subjected to
nonsense mediated messenger decay. Such corrective
splicing events leading to the upregulation of a rare splice
isoform have been described, albeit rarely, for other condi-
tions, such as spinal muscular atrophy (MIM: 253300),50
Rothmund-Thomson syndrome (MIM: 268400),51 retinitis
pigmentosa (MIM: 304020),52 Ullrich congenital muscular
dystrophy (MIM: 254090),53 and epidermolysis bullosa
(MIM: 226650).54 In these reported cases, the truncated
proteins were expressed and seemed to retain some residual
function that ameliorated the clinical phenotype. From
family D, we only had cultured fibroblasts, which entirely
lackedASCC1and inwhichwedidnot detect any corrective
splice isoforms that excluded the mutant exon (Figure 2).
Subcellular Location of the ASC-1 Complex
TRIP4 had been shown previously by indirect immunofluo-
rescence to be a nuclear protein that localized into the cyto-
plasm under conditions of serum deprivation.55 Because
TRIP4 forms a tetrameric protein complex,we hypothesized
that its correct subcellular localization might be compro-
mised if one subunit (e.g., TRIP4 or ASCC1) of the ASC-1
complexwas altered. Hence, we separated nuclear and cyto-
solic fractions of wild-type and ASCC1 mutant fibroblasts
under normal growth conditions, after serum depletion,
and after serum depletion with subsequent 30 and 60 min
of serum re-challenge and probed them on western blot
with antibodies directed against three subunits of the
ASC-1 complex (anti-TRIP4, anti-ASCC1, anti-ASCC2). We
were unable to confirma translocation to the cytoplasmun-
der serum starvation, neither of the entire ASC-1 complex
nor of TRIP4 alone. The signals of three subunits of the
ASC-1 complex remained stationary in the nuclear fraction
independently of the presence or absence of serum
(Figure S13).
Trip4 and Ascc1 Expression Analysis in Mouse
Embryos by In Situ Hybridization
To determine the spatial expression pattern of Trip4 and
Ascc1 in a later phase of embryonic development, we per-
formed in situ hybridization on cryosections of E17.5
mouse embryos. Both genes showed nearly identical
mRNA-expression patterns with ubiquitous expression,
albeit at different levels (Figure 4). Highest expression
was seen in dorsal root ganglia, the paraspinal sympathetic
and trigeminal ganglia, and thyroid and submandibular
glands, as well as the spinal cord. Expression in the cerebral
cortex was comparable to the expression in the spinal cord.
MO Knockdown of trip4 and ascc1 in Zebrafish
The function of TRIP4 and ASCC1 in vertebrates has not
been explored. To evaluate the physiological consequences
of the absence of both mutant proteins, we performed a
MO-mediated knockdown of trip4 and ascc1 in zebrafish,
given that both proteins are conserved between humans
and zebrafish (Figures S14 and S15). Based on the postmor-
tem findings regarding the affected children, which re-
vealed numerous apoptotic neurons in the anterior horn
of the spinal cord, and the muscle histology of prenatal
SMA, we focused our investigation on a-motoneuron and
muscle development. Indeed, we found a severe impair-
ment of axonal outgrowth, formation of the neuromus-
cular junction, and organization of themyotome (Figure 5,
Table S3). Control MO-injected embryos responded to
touch with typical coiling behavior, which consists of two
to three vigorous contractions of trunk and tail at 30
hpf.41 Knockdown of trip4 or ascc1 resulted in a compro-
mised response (Movies S1, S2, and S3, Table S3). The
knockout coiling phenotype of zebrafish could be rescuedThe Ameby injection of the respective full-length wild-type trip4
and ascc1 mRNA, but not by injection of mRNA carrying
the affected childrens’ mutations (Figure S11). To verify
the specificity of the used MO, we used a second MO
(MO2) aimed at a different splice site and were able to re-
produce the original effect (Figure S10, Table S4). These
loss-of-function analyses confirm that trip4 and ascc1 are
indispensable for motor system development. In accor-
dancewith theobservationof themotor behavior, themyo-
tomes, as well as the neuromuscular endplates, appeared
severely disorganized on electron microscopy (Figure 5).
Identification of ASC-1 Target Genes
In order to identify those genes whose mRNA transcript
levels are differently regulated in the absence of a function-
ally intact ASC-1 complex, we performed a global mRNA
expression analysis of ASCC1 mutant and control fibro-
blasts after serum depletion and re-challenge (Figure 6, Ta-
ble S6). Contrary to the originally published hypothesis
that the ASC-1 complex might regulate transcription via
the SRF,29 we discovered normal upregulation of the SRF-
dependent downstream target genes FOS (MIM: 164810),
IER2, FOSL1 (MIM: 1365150), FOSB (MIM: 164772), JUNB
(MIM: 165161), and TRIB1 (MIM: 609461) after serum
challenge that was indistinguishable between affected
and control fibroblasts (Figure S12). Hypothesis-free anal-
ysis of expression patterns after stringent filtering against
genes with a FDR >0.01 revealed downregulation of 44
genes (Figure 6, Table S6), 13 of which are involved in neu-
rogenesis (SERPINF1 [MIM: 172860], NOV [MIM: 164958]),
neuronal projection (SERPINF1, CRABP2 [MIM: 180231]),
pathfinding (SEMA3A [MIM: 603961], SEMA3D [MIM:
609907]), migration (DAB1 [MIM: 603448]), and suppres-
sion of neuronal apoptosis (SERPINF1, CRLF1 [MIM:
604237]). On the other hand, genes that suppress neuronal
plasticity (HAPLN1 [MIM: 115435]) and negatively regu-
late neuron projection (CDH13 [MIM: 601364]) were upre-
gulated. Six of the downregulated genes (Figure 6, Table S6)
are involved in the negative regulation of bone resorption
(TNFRSF11B [MIM: 602643]), ossification and regulation of
osteoblast differentiation (RASSF2 [MIM: 609492]), and
collagen fibril organization (DPT [MIM: 125597]), as well
as calcium ion homeostasis (FAM20A [MIM: 611062],
STC1 [MIM: 601185]).
Identification of ASC-1 Binding Partners
Immunoprecipitation with three different antibodies
(anti-TRIP4, anti-ASCC1, and anti-ASCC2) against sub-
units of the ASC-1 complex mutually copurified the other
members of the holocomplex (Figures 7 and S16–S18, Ta-
ble S7). Even in the absence of ASCC1, copurification be-
tween TRIP4 and ASCC2 was still possible (Figures S16
and S18), suggesting the stability of the complex even in
the absence of one subunit. Mass spectrometric analysis
of the immunoprecipitates consistently identified copurifi-
cation of the cysteine and glycine rich protein 1 (CSRP1), a
transcriptional cofactor that is known to be involved inrican Journal of Human Genetics 98, 473–489, March 3, 2016 481
Figure 4. Gene Expression Study in E17.5 Mouse Embryos
In situ hybridizations of cryosections from E17.5mouse embryos demonstrate the nearly identical expression patterns of Trip4 (A, C, and
E) and ofAscc1 (B, D, and F)mRNA. At the lower thoracic level (A and B), the highest expression levels were seen in the spinal cord, dorsal
root ganglia, paraspinal sympathetic ganglia, muscle, lung, and brown fat tissue. In the parasagittal sections, the highest expression
levels were seen on the thyroid and submandibular salivary gland and the trigeminal ganglion. Abbreviations are as follows: B, brain;
BFT, brown fat tissue; CB, cerebellum; DRG, dorsal root ganglion; GUT, gut; H, heart; KID, kidney; LIV, liver; LU, lung; PC, pancreas;
SC, spinal cord; SM, skeletal muscle; SMG, submandibular salivary gland; ST, sympathetic tract; TG, trigeminal ganglion; TG, thyroid
gland; TM; thymus; VC, vertebral column.spinal cord regeneration in adult zebrafish (Table S7, Fig-
ures S19–S23).56 Copurification of the CSRP1 protein was
additionally verified by western blot of all three anti-
ASC-1 immunoprecipitates with an anti-CSRP1 antibody
(Figure 7).482 The American Journal of Human Genetics 98, 473–489, March 3Discussion
Our data show that mutations in two genes that encode
different subunits (TRIP4 and ASCC1) of the activating
signal cointegrator 1 (ASC-1) complex cause a profound, 2016
Figure 5. Studies on Zebrafish Embryos
Expression of trip4 and ascc1 mRNA.
(A) trip4 is expressed ubiquitously in the head (A1) and trunk (A2)
at 24 hpf and at 48 hpf (A3 and A4). ascc1 is also expressed ubiq-
uitously in the head (A5) and trunk (A6) at 24 hpf and 48 hpf (A7
and A8). The arrowheads indicate the heart, verifying that both
trip4 and ascc1 are expressed in cardiac muscles.
(B) MO-mediated trip4 and ascc1 knockdown in zebrafish larvae
led to a severe derangement of a-motoneuron axons and the
The Amedisturbance of neuromotor unit development and result in
prenatal onset spinalmuscular atrophywithbone fractures.
The notion that these two proteins form a functional com-
plex and are involved in the same biological process in vivo
is supported (1) by the nearly identical mRNA-expression
pattern in the mouse embryo, (2) by the indistinguishable
phenotypes of trip4 and ascc1 zebrafish morphants, (3) by
mutual coimmunoprecipitation, and (4) ultimately by the
similar phenotype of affected children and zebrafish. Such
a phenomenon is known for other genetic disorders, such
as leukoencephalopathy with vanishing white matter,
which canbe causedby alterations in fivedifferent subunits
of the translation initiation factor eIF2B.57
The ASC-1 complex is composed of four subunits, which
bind to nuclear receptors and coactivate the transcription
of a wide range of transcripts. One subunit, TRIP4, was
initially identified as a transcriptional coactivator of the
thyroid hormone receptor.58 Later, it was shown that
TRIP4 stably associates with three other polypeptides, the
activating signal cointegrator subunits 1–3 (ASCC1–
ASCC3), and interacts with a wider range of transcription
factors such as activating protein 1 (AP-1), nuclear factor
kappa-B (NF-kB), and SRF.29 In particular, the latter interac-
tion between TRIP4 and SRF, which had been demon-
strated by reporter gene assays,29 seemed to offer a func-
tional link between genetic defect and disease phenotype
because SRF is an essential transcription factor for mus-
cle,59 nervous system,60,61 and bone62 development. How-
ever, we detected neither physical interaction between SRF
and ASC-1 (Figures S16–S18) nor abnormal SRF-dependent
transcription of downstream target genes in affected chil-
drens’ fibroblasts after serum depletion and re-challenge
(Figure S12).
To explore alternative explanations for the pathome-
chanism seen in the affected children studied here and tomyotome. In the morphants, we found a perturbed outgrowth
of a-motoneuron axons projecting to the trunk muscle in every
somite segment at 36 hpf. The a-motoneurons were short, thin,
and fragile with abnormal branches in trip4 morphants and
ascc1morphants. In these morphants, we additionally see ectopic
outgrowth of motoneurons from the spinal cord. The a-motoneu-
rons are labeled with the znp-1 antibody (green). Labeling with
a-bungarotoxin (purple) displays the formation of neuromuscular
junctions that form along with the a-motoneurons. The neuro-
muscular junctions were thin, reduced in number, and disorga-
nized in the trip4 and ascc1 morphants.
(C) Electron-microscopic images of axial sections through the
zebrafish myotome at 48 hpf. The rosette-like formation of myofi-
brils is greatly disturbed with reduced size and numbers. The lower
panels show a neuromuscular endplate of the control morphants
(left) with a normal thickened basal lamina, which is directly adja-
cent to the contractile elements of themyofibril. This is in contrast
to the endplates from the trip4 and ascc1 morphants, which are
smaller and have a disrupted basal lamina and no adjacent con-
tractile elements. An asterisk denotes clusters of neurotransmitter
vesicles (vesicle diameter 30–40 nm); open arrowheads denote the
synaptic cleft and basal lamina of the neuromuscular endplate;
open circles denote sarcomers (contractile elements) in the vicin-
ity of the neuromuscular endplate. Note the higher magnification
of the morphant endplate.
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Figure 6. Gene Expression Analysis of Wild-Type and ASCC1 Mutant Fibroblasts
(A) Clustergram of genes downregulated in fibroblasts of affected children with FDR < 0.01. Blue denotes normalized downregulation;
red denotes upregulation (see attached scale above). The numbers on the right identify the Affymetrix Human GeneChip 2.0 probe set.
The gene names are given on the far right column. The red arrows depict genes involved in neurogenesis; green arrows depict genes
involved in bone metabolism. Abbreviations are as follows: Co, control; Aff, affected individual with ASCC1 mutation; 00W, serum
starved for 12 hr; 30W, serum challenge for 30 min; 60W, serum challenge for 60 min; FDR, false discovery rate.
(B) Genes upregulated in fibroblasts of affected children with FDR < 0.01.
(C and D) Genes involved in neurogenesis that are downregulated (C) or upregulated (D) in ASCC1 mutant fibroblasts (red dots).
(E) Downregulated genes involved in bone metabolism and development (red dots). Each dot represents a separate hybridization exper-
iment. Black dots denote control individuals; red dots denote affected individuals. The horizontal lines represent the arithmetic mean.
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Figure 7. Coimmunoprecipitation of
CSRP1 with Three Subunits of the ASC-1
Complex
Immunoprecipitation was done with anti-
TRIP4, anti-ASCC1, and anti-ASCC2 anti-
bodies. For mock immunoprecipitation,
we used GAPDH antibodies, and for empty
controls, we used unloaded Protein-G-Se-
pharose beads. Western blots from input,
flow-through (unbound), and bound pro-
tein (elution) were serially incubated with
anti-TRIP4, anti-ASCC1, anti-ASCC2, as
well as with anti-CSRP1 antibodies.search for proteins that bind to ASC-1, we performed an
immunoprecipitation of the ASC-1 complex in fibroblasts
of affected children and controls. Using mass spectrometry
analysis, as well as western blot after immunoprecipita-
tion, we consistently found coimmunopurification of
CSRP1. CSRP1 localizes to the nucleus in the same manner
as the ASC-1 complex (Figure S13).
CSRP1 is an evolutionarily highly conserved 23.4 kDa
transcriptional coactivator that shares 83% identity be-
tween humans and zebrafish on the amino acid level. It
contains a double zinc-finger motif, a nuclear localization
signal, and a LIM motif, suggesting its involvement in
developmental processes.63,64 In the E14.5 mouse embryo,
strong expression can be found in the CNS, especially in
the spinal cord.65 MO-mediated knockdown of csrp1 in ze-
brafish during early development resulted in abnormal
axis formation and severe deformities of midline struc-
tures. Miyasaka et al. also demonstrated that Csrp1 inter-
acts with dishevelled 2 and diversin, thereby controlling
cell morphology and the generation of pseudopodial pro-
cesses via the non-canonical Wnt and JNK pathways.66
Both pathways largely influence the generation of filopo-
dia at axonal growth cones and are deemed essential for
neuronal polarity and axon outgrowth and branching, as
well as the navigation to their final targets. Interestingly,
in adult zebrafish, which have the capability to regrow sev-
ered descending spinal axons after spinal injury and regain
locomotor activity, Ma et al.56 demonstrate a direct influ-
ence of Csrp1 on the re-growth behavior of axons. In
contrast to mammals, zebrafish are able to reactivate spe-
cific developmental programs for regenerative purposes,
and Ma et al. found a significant upregulation of csrp1 in
those neurons that regrew their axons, whereas MO-medi-
ated csrp1 knockdown impaired axonal regeneration and
subsequent locomotor recovery.
We are aware that the conjectures about ASC-1 and
CSRP1 interaction have to be proven in a mammalian sys-The American Journal of Human Genetics 98, 473–489, March 3, 2016 485tem. It would thus be an interesting
line of research to investigate how
the simultaneous presence of ASC-1
and CSRP1 would shape neuronal
patterning, outgrowth, pathfinding,
and endplate formation. Because acomplete knockout of Csrp1 would most likely be embry-
onically lethal,66 such experiments would have to be
done in conditional knockout mice and with an a-moto-
neuron specific Cre-driver line.
Comparison of gene expression between mutant and
wild-type cells shows that the ASC-1 complex exerts an in-
fluence on entire modules of genes (Figure 6, Table S6),
many of which either enhance neurodevelopment and
pathfinding or whose products suppress other genes that
negatively regulate neuron projection, cell proliferation,
or neuronal plasticity. Despite the fact that the mRNA
expression analyses could only be done in the available
fibroblasts of the affected children, it has been shown
for another disease (MCT8-deficiency) that analysis of
genome-wide expression data from fibroblasts derived
from affected individuals was able to identify the dys-
regulation of coexpressed gene modules67 that are disease
specific and mirror those seen in the human brain tran-
scriptome.68
As an example from our cohort, SERPINF1 (serum pepti-
dase inhibitor F), the most prominently downregulated
gene (5.7-fold) in mutant fibroblasts, has been shown
to be involved in the positive regulation of spinal axon
sprouting,69 neuroprotection,70 and survival of spinal mo-
toneurons,71 whereas the extracellular matrix protein
HAPLN1 (hyaluronan and proteoglycan link protein), the
most prominently upregulated gene (þ6.7-fold) in mutant
fibroblasts suppresses neuronal plasticity.72 The same
modular phenomenon can be seen for genes involved in
bone development. Here, the TNFRSF11B (tumor necrosis
factor receptor superfamily, member 11b; osteoprotegerin)
gene was most prominently downregulated (4.8-fold).
Osteoprotegerin functions as an inhibitor of osteoclasto-
genesis73 and bone resorption74 and positively regulates
bone mass.75
In conclusion, theASC-1 complex seems to be involved in
the highly regulated development of the neuromuscular
unit andpossiblyof theneighboringbony structures aswell.
However, further research is needed to elucidate the exact
signaling pathways that are involved in the patterning and
development of the neuromuscular unit via the ASC-1 com-
plex. Knowledge about the factors involvedmight have im-
plications for regenerative medicine.Accession Numbers
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